Pazopanib

Generic Name
Pazopanib
Brand Names
Votrient
Drug Type
Small Molecule
Chemical Formula
C21H23N7O2S
CAS Number
444731-52-6
Unique Ingredient Identifier
7RN5DR86CK
Background

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions
Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Associated Therapies
-
Clinical Trials
Related News

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

Phase 1
Completed
Conditions
Gynecologic Tumors
Interventions
Drug: Oral Topotecan
Drug: Pazopanib
First Posted Date
2008-12-02
Last Posted Date
2017-03-28
Lead Sponsor
Vector Oncology
Target Recruit Count
33
Registration Number
NCT00800345
Locations
🇺🇸

The West Clinic, Memphis, Tennessee, United States

Adjuvant Pazopanib in Stage I NSCLC

Phase 2
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Placebo
Drug: PAZOPANIB
First Posted Date
2008-10-20
Last Posted Date
2019-09-24
Lead Sponsor
Intergroupe Francophone de Cancerologie Thoracique
Target Recruit Count
142
Registration Number
NCT00775307
Locations
🇫🇷

Mont de Marsan - CH, Mont de Marsan, France

🇫🇷

Marseille - Hôpital Sainte Marguerite, Marseille, France

🇫🇷

Strasbourg - NHC, Strasbourg, France

and more 37 locations

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

Phase 3
Completed
Conditions
Sarcoma, Soft Tissue
Interventions
Drug: Placebo
Drug: PAZOPANIB
First Posted Date
2008-09-16
Last Posted Date
2013-08-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
369
Registration Number
NCT00753688
Locations
🇬🇧

GSK Investigational Site, Sheffield, United Kingdom

An Extension to Study MD7108240

Phase 2
Completed
Conditions
Macular Degeneration
Interventions
Drug: Pazopanib
First Posted Date
2008-08-13
Last Posted Date
2017-12-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
42
Registration Number
NCT00733304
Locations
🇮🇹

GSK Investigational Site, Padova, Veneto, Italy

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Phase 1
Completed
Conditions
Solid Tumours
Interventions
Drug: topotecan
Drug: pazopanib
First Posted Date
2008-08-12
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
68
Registration Number
NCT00732420
Locations
🇳🇱

GSK Investigational Site, Utrecht, Netherlands

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Phase 2
Completed
Conditions
Renal Cell Carcinoma
Interventions
Drug: Pazopanib
First Posted Date
2008-08-08
Last Posted Date
2015-05-20
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
57
Registration Number
NCT00731211
Locations
🇺🇸

Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States

🇺🇸

Northeast Georgia Medical Center, Gainesville, Georgia, United States

🇺🇸

Baptist Hospital East, Louisville, Kentucky, United States

and more 14 locations

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 3
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Sunitinib
Drug: Pazopanib
First Posted Date
2008-07-23
Last Posted Date
2021-05-13
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
927
Registration Number
NCT00720941
Locations
🇬🇧

Novartis Investigative Site, Swansea, United Kingdom

Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function

Phase 1
Completed
Conditions
Neoplasms
Lymphoma
First Posted Date
2008-05-07
Last Posted Date
2019-11-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
8
Registration Number
NCT00674024
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

First Posted Date
2008-02-21
Last Posted Date
2017-11-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
58
Registration Number
NCT00619424
Locations
🇮🇹

GSK Investigational Site, Orbassano (TO), Piemonte, Italy

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

Phase 2
Completed
Conditions
Macular Degeneration
Interventions
Drug: Pazopanib
First Posted Date
2008-02-11
Last Posted Date
2017-11-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
70
Registration Number
NCT00612456
Locations
🇮🇹

GSK Investigational Site, Padova, Veneto, Italy

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy